LB-102

DB19214InvestigationalSmall molecule

LB-102 is under investigation in clinical trial NCT06179108 (Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia).

Mechanism: Pharmacologically active on Dopamine receptor D3, 5-hydroxytryptamine receptor 7, and Dopamine receptor D2
Curator reviewed
Formula / weight: C₁₈H₂₉N₃O₄S · 383.51 g/mol (avg)
Also known as: Benzamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-4-(methylamino)- · N'-methyl amisulpride · N'-methylamisulpride
Code names: LB-102

Resolves to

Compound

UNIIN81WKW91XFCAS2227154-23-4ChEMBLCHEMBL4594422

Structure

InChIKeyNXKXZXNNWRYXRE-UHFFFAOYSA-NSMILESCCN1CCCC1CNC(=O)C1=CC(=C(NC)C=C1OC)S(=O)(=O)CC

Targets

P35462DRD3P34969HTR7P14416DRD2

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with LB-102, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account